Name: Pulmonary Arterial Compliance and the FREEDOM-EV study
Uploaded: 2025-02-04T00:00:00.0000000
Duration: T00H02M42S
Description: Pulmonary Arterial Compliance and the FREEDOM-EV study

Name: Pulmonary Arterial Compliance and the FREEDOM-EV study

Description: Pulmonary Arterial Compliance and the FREEDOM-EV study

Thumbnail URL: https://cadmoremediastorage.blob.core.windows.net/1a091133-9574-4559-89f6-08cfebf1e45b/videoscrubberimages/Scrubber_8.jpg

Duration: T00H02M42S

Embed URL: https://stream.cadmore.media/player/1a091133-9574-4559-89f6-08cfebf1e45b

Content URL: https://cadmoreoriginalmedia.blob.core.windows.net/1a091133-9574-4559-89f6-08cfebf1e45b/Unither_PostProduction_Complete.MP4?sv=2019-02-02&sr=c&sig=fpYus6mBxlvJv7oj920H4G9iCnxVmgBNXYNkbVvxOlo%3D&st=2025-02-11T23%3A42%3A38Z&se=2025-02-12T01%3A47%3A38Z&sp=r

Upload Date: 2025-02-04T00:00:00.0000000

Transcript: Language: EN.
Segment:1 Pulmonary artery compliance.
What is pulmonary artery compliance, PAC, and why is it an important marker of disease progression in pulmonary arterial hypertension, PAH? PAC is a measure of arterial distensibility, the ability of a vessel to expand or relax, and it's important for ensuring a steady flow of blood during the pressure changes of the cardiac cycle. Healthy arteries are easily distensible, expanding during high pressure and relaxing during low pressure to help modulate blood flow from the right ventricle to the lungs. However, if the arteries lose distensibility, such as with the vasculopathy associated with PAH, they stiffen and are unable to accommodate changes in pulsatile pressure. This results in an increased pulsatile load and increased pressure on the right ventricle of the heart. Early in PAH, arterial compliance remains relatively high. As the disease progresses, the pulmonary arteries stiffen and PAC is reduced, often before pulmonary vascular resistance, PVR, increases. Decreases in PAC have been shown to be a significant predictor of mortality in PAH.
Segment:2 Oral treprostinil and the FREEDOM-EV trial.
Oral treprostinil is a prostacyclin mimetic indicated for the treatment of group 1 PAH to improve exercise capacity and delay disease progression. A 24-week substudy of the freedom FREEDOM-EV clinical trial examined the hemodynamic effects of oral treprostinil in 61 participants and found that oral treprostinil significantly increased PAC by 26.4% when compared to baseline. Additionally, the study found that cardiac output increased by 11.3% and PVR decreased by 21.5% when compared to baseline. These data suggest that increased compliance is an integral part of the physiological mechanism by which oral treprostinil delays disease progression. Read more details in the publication. "Oral treprostinil improves pulmonary vascular compliance in pulmonary arterial hypertension." in pulmonary arterial hypertension." in pulmonary arterial hypertension."
Segment:3 Acknowledgements and disclosures.

Cadmore media player playing video Pulmonary Arterial Compliance and the FREEDOM-EV study

Video Player

Transcript

Segments

End of Video Player Control